Journal: Breast Cancer : Targets and Therapy

Article Title: Identification of genes involved in breast cancer and breast cancer stem cells

doi: 10.2147/BCTT.S85202

Figure Lengend Snippet: Gene expression among different cancer types. Notes: Relative gene expression analysis of nine genes that were overexpressed in breast cancer and breast CSCs. The gene expression also was studied in colon and lung cancer, colon CSCs, lung CSCs, embryonic stem cells, and in a reference sample. The experiments were performed in triplicate and a P -value of <0.05 was considered significant. Abbreviations: CSCs, cancer stem cells; ESCs, embryonic stem cells; HP , haptoglobin; SMPD1 , sphingomyelin phosphodiesterase 1, acid lysosomal; SCRIB , scribbled homolog ( Drosophila ); KCMF1 , potassium channel modulatory factor 1; FAM155B , family with sequence similarity 155, member B; PTGER3 , prostaglandin E receptor 3 (subtype EP3); GPR3 , G protein-coupled receptor 3; TMX2 , thioredoxin-related transmembrane protein 2; DDX49 , DEAD (Asp-Glu-Ala-Asp) box polypeptide 49.

Article Snippet: During the exponential phase of proliferation, commercial breast CSCs cells were plated in 24-well plates (E36102-29-24Well; Celprogen) and transfected with gene-specific small interfering RNAs (siRNAs) using Lipofectamine 2000 Reagent (11668-027; Thermo Fisher Scientific), according to the manufacturer’s instructions.

Techniques: Expressing, Sequencing

Journal: Breast Cancer : Targets and Therapy

Article Title: Identification of genes involved in breast cancer and breast cancer stem cells

doi: 10.2147/BCTT.S85202

Figure Lengend Snippet: Breast CSCs pre- and post-siRNA knockdown. Note: Representative images showing breast CSCs pre- and post-siRNA knockdown. Abbreviations: CSCs, cancer stem cells; siRNA, small interfering RNA; TMX2 , thioredoxin-related transmembrane protein 2; FAM155B , family with sequence similarity 155, member B; PTGER3 , prostaglandin E receptor 3 (subtype EP3); GPR3 , G protein-coupled receptor 3; DDX49 , DEAD (Asp-Glu-Ala-Asp) box polypeptide 49.

Article Snippet: During the exponential phase of proliferation, commercial breast CSCs cells were plated in 24-well plates (E36102-29-24Well; Celprogen) and transfected with gene-specific small interfering RNAs (siRNAs) using Lipofectamine 2000 Reagent (11668-027; Thermo Fisher Scientific), according to the manufacturer’s instructions.

Techniques: Small Interfering RNA, Sequencing

Journal: Breast Cancer : Targets and Therapy

Article Title: Identification of genes involved in breast cancer and breast cancer stem cells

doi: 10.2147/BCTT.S85202

Figure Lengend Snippet: Gene expression of stemness transcription factors in breast CSCs. Notes: Relative gene expression of transcription factors in breast CSCs following knockdown. The ∆∆Ct method was used to perform the analysis. Each bar represents the average of the Ct values. The assays were performed in triplicate and a P -value of <0.05 was considered to be significant. The assays are presented in a log2 scale. Thus, positive values indicate overexpression while negative values indicate underexpression. Abbreviations: CSCs, cancer stem cells; TMX2 , thioredoxin-related transmembrane protein 2; FAM155B , family with sequence similarity 155, member B; PTGER3 , prostaglandin E receptor 3 (subtype EP3); GPR3 , G protein-coupled receptor 3; DDX49 , DEAD (Asp-Glu-Ala-Asp) box polypeptide 49; NANOG , Homeobox protein NANOG; OCT3/4 , Octamer-binding transcription factor ¾; SOX2 , sex determining region Y-box 2; CD34 , Hematopoietic progenitor cell antigen CD34.

Article Snippet: During the exponential phase of proliferation, commercial breast CSCs cells were plated in 24-well plates (E36102-29-24Well; Celprogen) and transfected with gene-specific small interfering RNAs (siRNAs) using Lipofectamine 2000 Reagent (11668-027; Thermo Fisher Scientific), according to the manufacturer’s instructions.

Techniques: Expressing, Over Expression, Sequencing, Binding Assay

Journal: Acta pharmacologica Sinica

Article Title: Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest.

doi: 10.1038/s41401-020-0404-8

Figure Lengend Snippet: Fig. 6 Avasimibe induced cell cycle arrest in the U251 and U87 cells. a Western blot analysis showed that avasimibe induced cell cycle arrest in the G0/G1 phase by regulating the p53/p21/p27 pathway. b Western blot analysis showed that avasimibe arrested the cell cycle in the G2/M phase by regulating the p53/GADD45A and Aurora A/PLK1 pathways. c Schematic model for the mechanism of avasimibe in cell cycle arrest

Article Snippet: The primary antibodies against cleaved caspase-9, cleaved PARP, p21, p27, CDK2, cyclin E1, CDK4, cyclin D, and PLK1 were purchased from Cell Signaling Technology; antibodies against Bax, p53, Aurora A, CDK1, cyclin B1, and GAPDH were purchased from Proteintech.

Techniques: Western Blot

Journal: Journal of Cellular and Molecular Medicine

Article Title: Ailanthone synergizes with PARP1 inhibitor in tumour growth inhibition through crosstalk of DNA repair pathways in gastric cancer

doi: 10.1111/jcmm.18033

Figure Lengend Snippet: AIL with OLP blocks HSP90‐BRCA1 and PARP1 activity. The protein expression of HSP90, BRCA1, PARP1 in two GC cell lines after treated with a blank control group, OLP, AIL and OLP + AIL group. (B) The protein expression of HSP90, BRCA1 in two GC cell lines after being treated with a specified concentration of AIL for 24 h. (C) Pull‐down of selected proteins with HSP90 in the nucleus and cytoplasm of GC cells treated with AIL for 24 h, and then the IP fractions were immunoblotted with HSP90, BRCA1 and GAPDH. (D) Representative images of HSP90, BRCA1 and PARP1 in PDX tumour tissue as detected via immunohistochemistry. Scale bars, 200 μm. (E) Data were derived from experiments conducted in triplicate in (D). The PDX tumour tissues were compared with the control group, * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: BRCA1 (1:100, Proteintech, 22362‐1‐AP).

Techniques: Activity Assay, Expressing, Control, Concentration Assay, Immunohistochemistry, Derivative Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: Ailanthone synergizes with PARP1 inhibitor in tumour growth inhibition through crosstalk of DNA repair pathways in gastric cancer

doi: 10.1111/jcmm.18033

Figure Lengend Snippet: AIL inhibits BRCA1 through downregulating P23 and inevitably suppress the HR pathway of GC. Western blotting was performed to detect the expression of P23, HSP90 and BRCA1 in AGS and SGC7901 cells after treatment with a specified concentration of CEL (P23 inhibitor) for 24 h. (B) The mRNA expression of P23 in two GC cell lines (AGS and SGC7901) after being treated with P23 shRNA lentivirus. (C) The protein expression of P23, HSP90 and BRCA1 in two GC cell lines after being treated with shP23‐1, shP23‐2 and shP23‐3. (D‐F) BALB/C nude mice are implanted with shNC or shP23‐3 GC cells subcutaneously. (D) The images of subcutaneous tumour nodules formed in two groups of mice. (E) Representative images of P23, HSP90 and BRCA1 in CDX tumour tissue as detected via immunohistochemistry. Scale bars, 50 μm. (F) Data were derived from experiments conducted in triplicate in (E).

Article Snippet: BRCA1 (1:100, Proteintech, 22362‐1‐AP).

Techniques: Western Blot, Expressing, Concentration Assay, shRNA, Immunohistochemistry, Derivative Assay